U.S. Panel Sees Amgen And Johnson & Johnson Anemia Drug Risks In Kidney Patients
BALTIMORE, Md., March 24 (Reuters) - Use of controversial anemia drugs made by Amgen Inc (AMGN.O) and Johnson & Johnson (JNJ.N) at high levels likely worsen heart problems and possibly chances for survival in kidney patients, a U.S. Medicare advisory panel said on Wednesday, calling for more study.